CoreAge Rx vs Oak
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Oak head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 43 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make Oak a bad call — it's best for readers weighing oak specifically who want to know what it does and does not publish before handing over 29 questions' worth of medical history — not readers trying to compare a price today. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Oak | |
|---|---|---|
| Brief Score | 94/100 (A) | 43/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | $250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning |
| Coverage | US only; restrictions by state, confirmed at intake | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
Oak: Re-read twice on 15 August 2026 with a real browser and no form input, and the figures MOVED BETWEEN THE TWO READS. In the morning its order form showed $200/mo for compounded semaglutide and $250 for tirzepatide; that afternoon, same URL, same entry path, browser storage cleared as a control, it showed $250 and $300 with the strike-throughs gone and every brand line $100 higher. What is stable is WHERE the price is: on the first screen of its order form, before a single question. The tracker previously carried no figure because the ladder was believed to be behind a 29-question intake — it is not, it is in front of it. What remains true is that Oak advertises nine different "starting" prices at once — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — attaches a term to none, and that its headline "$133 / $199" is the three-month prepay under code OAKSAVE200, billed upfront.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.